Monopar Therapeutics Inc. Payments to Acquire Short-term Investments
Monopar Therapeutics Inc. (MNPR) reported Payments to Acquire Short-term Investments of $88.42 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireShortTermInvestments · last filed 2026-08-12
- Monopar Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2026-06-30 was $47.58M, a 3823.83% increase year-over-year.
- Monopar Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2026-03-31 was $40.84M, a 2020.52% increase year-over-year.
- Monopar Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2025-12-31 was $78.29M, a 446.01% increase year-over-year.
- Monopar Therapeutics Inc. payments to acquire short-term investments for the quarter ending 2025-09-30 was $5.73M.
- Monopar Therapeutics Inc. payments to acquire short-term investments for fiscal 2025 was $87.15M, a 468.73% increase from fiscal 2024.
- Monopar Therapeutics Inc. payments to acquire short-term investments for fiscal 2024 was $15.32M, a 94.42% increase from fiscal 2023.
- Monopar Therapeutics Inc. payments to acquire short-term investments for fiscal 2023 was $7.88M, a 60.25% increase from fiscal 2022.
- Monopar Therapeutics Inc. payments to acquire short-term investments for fiscal 2022 was $4.92M.
| Period end | Payments to Acquire Short-term Investments 3 month | Payments to Acquire Short-term Investments 6 month | Payments to Acquire Short-term Investments 9 month | Payments to Acquire Short-term Investments 12 month |
|---|---|---|---|---|
| 2026-06-30 | $47.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $88.42M 10-Q · filed 2026-08-12 | $166.71M derived: sum of 3 quarters · filed 2026-08-12 | $172.44M derived: sum of 4 quarters · filed 2026-08-12 |
| 2026-03-31 | $40.84M 10-Q · filed 2026-05-14 | $119.13M derived: sum of 2 quarters · filed 2026-05-14 | $124.85M derived: sum of 3 quarters · filed 2026-05-14 | $126.06M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-12-31 | $78.29M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $84.01M derived: sum of 2 quarters · filed 2026-03-27 | $85.23M derived: sum of 3 quarters · filed 2026-08-12 | $87.15M 10-K · filed 2026-03-27 |
| 2025-09-30 | $5.73M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $6.94M derived: sum of 2 quarters · filed 2026-08-12 | $8.86M 10-Q · filed 2025-11-13 | $23.20M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-06-30 | $1.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-12 | $3.14M 10-Q · filed 2026-08-12 | $17.48M derived: sum of 3 quarters · filed 2026-08-12 | $17.48M derived: sum of 4 quarters · filed 2026-08-12 |
| 2025-03-31 | $1.93M 10-Q · filed 2026-05-14 | $16.26M derived: sum of 2 quarters · filed 2026-05-14 | $16.26M derived: sum of 3 quarters · filed 2026-05-14 | $16.27M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | $14.34M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-27 | $14.34M derived: sum of 2 quarters · filed 2026-03-27 | $14.34M derived: sum of 3 quarters · filed 2026-03-27 | $15.32M 10-K · filed 2026-03-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $2.42K derived: sum of 2 quarters · filed 2025-11-13 | $985.73K 10-Q · filed 2025-11-13 | $976.49K derived: sum of 4 quarters · filed 2025-11-13 |
| 2024-06-30 | $2.42K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | $985.73K 10-Q · filed 2025-08-12 | $976.49K derived: sum of 3 quarters · filed 2025-08-12 | $3.95M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | $983.31K 10-Q · filed 2025-05-13 | $974.07K derived: sum of 2 quarters · filed 2025-05-13 | $3.94M derived: sum of 3 quarters · filed 2025-05-13 | $5.91M derived: sum of 4 quarters · filed 2025-05-13 |
| 2023-12-31 | -$9.24K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $2.96M derived: sum of 2 quarters · filed 2025-03-31 | $4.92M derived: sum of 3 quarters · filed 2025-03-31 | $7.88M 10-K · filed 2025-03-31 |
| 2023-09-30 | $2.97M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-08 | $4.93M derived: sum of 2 quarters · filed 2024-11-08 | $7.89M 10-Q · filed 2024-11-08 | $12.81M derived: sum of 4 quarters · filed 2024-11-08 |
| 2023-06-30 | $1.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $4.92M 10-Q · filed 2024-08-09 | $9.84M derived: sum of 3 quarters · filed 2024-08-09 | $9.84M derived: sum of 4 quarters · filed 2024-08-09 |
| 2023-03-31 | $2.96M 10-Q · filed 2024-05-09 | $7.88M derived: sum of 2 quarters · filed 2024-05-09 | $7.88M derived: sum of 3 quarters · filed 2024-05-09 | |
| 2022-12-31 | $4.92M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-28 | $4.92M derived: sum of 2 quarters · filed 2024-03-28 | $4.92M 10-K · filed 2024-03-28 | |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $0.00 10-Q · filed 2023-11-09 | ||
| 2022-06-30 | $0.00 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |